Davide Capodanno, MD, PhD Associate Professor, University of Catania, Italy
|
|
- Crystal Price
- 5 years ago
- Views:
Transcription
1 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 1 Autumn in Lucca V Simposio - 28 Novembre PM-4.45PM L incubo del paziente e le incognite del cardiologo: la restenosi intrastent resta un problema fisiopatologico ancora irrisolto? Davide Capodanno, MD, PhD Associate Professor, University of
2 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 2 Utilization of Stent Type and In-Stent Restenosis 10,004 PCI patients with follow-up angiography from the DHZ Restenosis registry First Generation DES: 8/ /2005 Second Generation DES: from 1/2006 Restenosis First Generation DES Second Generation DES Cassese S. et al. Heart. 2014;100:153-9
3 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 3 Prognostic Role of In-Stent Restenosis 10,004 PCI patients with follow-up angiography from the DHZ Restenosis registry (26.4% ISR) Predictors of 4-year mortality HR 95% CI P value Restenosis at routine control angiography Age (for each 10-year increase) <0.001 Diabetes mellitus <0.001 Current smoking habit Left ventricular ejection fraction (for each 5% decrease) <0.001 Female gender <0.001 The impact of restenosis was confirmed in asymptomatic patients undergoing routine control angiography. Mortality was not impacted by the decision to perform TVR Cassese S. et al. Eur Heart J [Epub ahead of print]
4 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 4 Restenosis: Angiographic Definition Restenosis Recurrent diameter stenosis >50% at the stent segment or its edges (5-mm segments adjacent to the stent) Mehran R, et al. Circulation. 1999;100:
5 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 5 OCT: New Avenues for Tissue Characterization Homogeneous bright neointimal proliferation Uniform neointimal proliferation with microvessels Layered pattern with multiple microvessels in the dark layer overlying the stent struts Multilayered pattern Alfonso F, et al. J Am Coll Cardiol. 2014;63:
6 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 6 BMS-ISR and DES-ISR: Different Entities? Magnification images of restenosis within BMS and a DES, both implanted 5 years antemortem smooth muscle cell-rich neointimal hyperplasia neoatherosclerosis with formation of a necrotic core chronic inflammation with neovascularization around stent struts neoatherosclerosis with calcification BMS DES Joner M, CVPath Inc., Gaithersburg, Maryland
7 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 7 Features of Restenotic Tissue in BMS and DES Imaging features BMS restenosis DES restenosis Angiographic morphology Diffuse pattern more common Focal pattern more common OCT tissue properties Homogeneous, high-signal band most common Layered structure or heterogeneous most common Time course of late luminal loss Late loss maximal by 6-8 months Ongoing late loss out to 5 years Histopathological features Smooth muscle cellularity Rich Hypocellular Proteoglycan content Moderate High Peri-strut fibrin and inflammation Occasional Frequent Complete endothelialization 3-6 months Up to 48 months Thrombus present Occasional Occasional Neoatherosclerosis Relatively infrequent, late Relatively frequent, accelerated Alfonso F, et al. J Am Coll Cardiol. 2014;63:
8 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 8 Underlying Mechanisms of Restenosis 1. Stent underexpansion Underdeployment due to undersizing Underlying heavily calcified lesion 2. Geographical missing ( candy wrapper restenosis) Stent misplacement Stents not fully covering the underlying lesion 3. Stent fracture 4. Drug resistance and local hypersensitivity reactions Alfonso F, et al. J Am Coll Cardiol. 2014;63:
9 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 9 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
10 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 10 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
11 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 11 Plain Old Balloon Angioplasty (POBA) 1. Technically straigthforward 2. Satisfactory acute results, particularly in focal patterns, but high long-term restenosis rates 3. Technique Review the index procedure Favors noncompliant s to avoid dog bone effects, with a 1.1:1 -to-artery ratio. Target the narrowing rather than the entire stented segment Avoid slippage outside the stent ( watermelon seeding phenomenon) 4. Outdated
12 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 12 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
13 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 13 Cutting Standard catheter with lateral blades Offers protection against watermelon seeding, anchoring the within the target lesion, preventing slippage related problems Deeply incises neointimal tissue and, at least theoretically, may favor subsequent extrusion Superior than POBA in reducing slippage and need for unplanned stent implantation (RESCUT trial)
14 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 14 Scoring (Angiosculpt) Nitinol scoring element with three spiral struts that wrap around the OCT Image ISR Lesion Prior- and Post- AngioSculpt demonstrating scoring Takano et al. Int J Cardiol. 2010;141:51-3
15 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 15 Scoring ballons in DES-ISR treated with DCB ISAR-DESIRE 4 N=250 Patients undergoing DCB angioplasty of DES-ISR R 1:1 Scoring ballon + DCB DCB alone Primary Endpoint In-segment percent diameter stenosis at 6-8 months follow-up angiography Estimated Study Completion Date: December 2015 NCT
16 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 16 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
17 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 17 Debulking Techniques Excimer Laser Showed good results in selected cases but eventually proved to have poorer ablation capability compared with rotational atherectomy 1 Rotational atherectomy Failed to show benefit compared with angioplasty alone in BMS-ISR (ARTIST trial). May still be required as a bailout strategy in patients with undilatable ISR lesions 2 1 Mehran R, et al. Circulation 2000;101: Von Dahl J, et al. Circulation 2002;105:583 8
18 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 18 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
19 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 19 Brachytherapy versus DES for BMS-ISR SIRS: 384 patients with BMS-ISR 2:1 randomized to vascular brachytherapy or SES TAXUS V ISR: 396 patients with BMS-ISR 1:1 randomized to vascular brachytherapy or PES Angiographic restenosis at Follow-up P=0.07 P<0.001 Holmes Dr Jr et al, JAMA 2006;295: Stone GW, et al, JAMA 2006;295:
20 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 20 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
21 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 21 POBA versus BMS for BMS-ISR RIBS: 450 patients with BMS-ISR randomized to POBA or sandwich BMS After the procedure Stent (N=224) POBA (N=226) P value Minimal lumen diameter (mm) 2.77± ±0.5 <0.001 Stenosis (% of lumen diameter) 12±10 23±10 <0.001 Acute gain (mm) 2.08± ±0.5 <0.001 After the procedure ( in-lesion ) Minimal lumen diameter (mm) 1.69± ± Stenosis (% of lumen diameter) 43±24 45± Restenosis (%) 33% 38% 0.36 Late loss (mm) 1.06± ±0.7 <0.001 In patients with large vessels ( 3 mm) and restenosis located at the stent edge, stenting exhibited better results Alfonso F, et al. J Am Coll Cardiol 2003;42:
22 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 22 POBA versus DES for BMS-ISR ISAR-DESIRE: 300 patients with BMS-ISR randomized to POBA, SES or PES RIBS 2: 150 patients with BMS-ISR randomized to POBA or PES Target vessel revascularization at 9 months P< P=0.03 Kastrati A, et al. JAMA 2005;293: Alfonso F. J. Am Coll Cardiol 2006;47:
23 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 23 Same DES versus Switch DES for DES-ISR ISAR-DESIRE 2: 450 patients with SES-ISR randomized to SES or PES P=0.69 P=0.52 Mehilli J. Et al. J Am Coll Cardiol 2010;55:2710 6
24 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 24 Bioresorbable Scaffolds for DES-ISR? Rationale The device should eventually disappear from the vessel wall, avoiding the presence of multiple stent layers ( onion skin ) Unkowns Lumen crowding due to strut thickness Device flexibility that may affect access to restenotic lesions Questions regarding radial strength and recoil Alfonso F, et al. J Am Coll Cardiol 2014;63:2875
25 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 25 Management Strategies for ISR Conventional angioplasty Cutting and scoring therapy Debulking techniques Vascular Brachiterapy Repeat Stenting Drug-coated angioplasty
26 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 26 DCB versus EES for BMS-ISR RIBS V: 189 patients with BMS-ISR randomized to DCB or EES Minimum Lumen Diameter at Follow-up P< P< Binary restenosis and clinical events at 1 year were low and similar in both groups Alfonso F., et al. J Am Coll Cardiol 2014;63:
27 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 27 DCB versus PES versus POBA for DES-ISR ISAR DESIRE 3: 402 patients with BMS-ISR randomized to DCB or EES Cumulative Frequency (%) PEB 38.0% PES 37.4% PEB versus PES P non-inferiority =0.007 Paclitaxel-Eluting Balloon (PEB) Paclitaxel-Eluting Stent (PES) Balloon Angioplasty (BA) Diameter Stenosis at Follow-up Angiography (%) PEB versus BA PES versus BA P superiority <0.001 BA 54.1% Byrne RA, et al. Lancet 2013;381:461 7
28 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 28 DCB versus EES for DES-ISR RIBS IV: 189 patients with BMS-ISR randomized to DCB or EES Minimum Lumen Diameter at Follow-up P=0.004 P<0.001 EES also provided better late clinical results, driven by a significant reduction in TLR Alfonso F., et al. TCT 2014, Washington DC
29 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide ESC/EACTS Guidelines on myocardial revascularization Management of restenosis Repeat PCI is recommended, if technically feasible. I C DES are recommended for the treatment of in-stent re-stenosis (within BMS or DES). Drug-coated s are recommended for the treatment of in-stent restenosis (within BMS or DES). IVUS and/or OCT should be considered to detect stent-related mechanical problems. I I IIa A A C Windecker et al. Euro Heart J 2014 [Ahead of print]
30 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 30 Closing Remarks / 1 1. Although the advent of DES has reduced the incidence of ISR, treatment of this clinical entity remains a prevailing clinical problem. 2. The substrate of ISR encompasses a pathological spectrum ranging from smooth muscle cell proliferation to neoatherosclerosis. 3. Intracoronary imaging provides unique insights into the underlying etiology of ISR, but its role in optimizing the clinical results of these reinterventions still remains unsettled.
31 Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 31 Closing Remarks / 2 4. Among currently available therapeutic modalities, DES and DCB provide the best clinical and angiographic results in patients with ISR In a fast-evolving field, second generation DES were recently found to be better than DCB for DES-ISR in RIBS IV DCB may be preferred over DES in patients with ISR and multiple metal layers, in those with large side branches, and in those at high bleeding risk undergoing prolonged dual antiplatelet therapy. 5. CABG should be considered for frequent flyers patients, although this will usually be dictated by the prognostic relevance of the restenotic lesion. dcapodanno@gmail.com
In-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationComplex PCI. Your partner in complex PCI: In-stent restenosis (ISR)
Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationTratamiento de la Reestenosis del Stent Farmacoactivo
XXXI Jornadas SOLACI. 10ª Región CONOSUR LIIIº Congreso Chileno de Cardiología y Cirugía Cardiovascular Hotel Patagónico. Puerto Varas. Chile (30 Nov 1 Dic 2016) Tratamiento de la Reestenosis del Stent
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationDCB for Coronary ISR Impact of Lesion Preparation Bruno Scheller
DCB for Coronary ISR Impact of Lesion Preparation Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III, Universitätsklinikum
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationIn-Stent Restenosis. Can we kill it?
In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of
More informationChallenges of in-stent Restenosis. The Balloon Approach
Challenges of in-stent Restenosis The Balloon Approach Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III,
More informationRESTENOSIS Facing up to the problem
RESTENOSIS Facing up to the problem Petr Kala University Hospital Brno Czech Republic ESC 2011, Paris Disclosure Scientific Advisory Boards or Education presentations fee Abbott, Boston Scientific, Cordis
More informationIncidence and Treatment for LM In-Stent
Incidence and Treatment for LM In-Stent Restenosis Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology
More information2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:
Pathology of In-stent Neoatherosclerosis in BMS and DES 197 BMS, 103 SES, and 106 PES with implant duration >30 days The incidence of neoatherosclerosis was significantly greater in DES (31%) than BMS
More informationSeQuent Please World Wide Registry
Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationInsights in Thrombosis and In-Stent Restenosis
Clinical Value of OCT Insights in Thrombosis and In-Stent Restenosis Fernando Alfonso MD, PhD, FESC Interventional Cardiology. Cardiovascular Institute. Clinico San Carlos University Hospital. Madrid.
More informationEffectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis
Journal of the American College of Cardiology Vol. 49, No. 5, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.049
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationThe titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath
The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationWhat Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas
What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas Stent Era Lessons on Vessel Preparation Under expanded stent consequences Abrupt
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationPaclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2285-2292, 2015 Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data JUN LI, WAN
More informationRationale and algorithm for below-the-knee acute gain optimization
Leipzig, 01 Feb. 2018 Rationale and algorithm for below-the-knee acute gain optimization Flavio Airoldi, MD Flavio Airoldi Multimedica IRCCS Milan ITALY flavio.airoldi@multimedica.it Rationale Restenosis
More informationΑγγειοπλαστική με απλό μπαλόνι και με μπαλόνια που αποδεσμέουν φαρμακευτική ουσία.
7 ο Συνέδριο Επεμβατικής Καρδιολογίας και Ηλεκτροφυσιολογίας, Καρδιολογική Εταιρεία Βορείου Ελλάδος, 9-11/10/2014, Θεσσαλονίκη Αγγειοπλαστική με απλό μπαλόνι και με μπαλόνια που αποδεσμέουν φαρμακευτική
More informationComparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006)
Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006) 97;1182-7 n&list_uids=16616023 Value of the American College
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationSirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR
Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR DR. SAMEER I DANI Director, Department of Cardiology, Apollo Hospital & Life Care Institute (LIMSAR), Ahmedabad, India. IN STENT RESTENOSIS
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More information4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationOptical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent
Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent heart institute, Division of cardiology, Tokyo, Japan Yusuke Watanabe, Ryuta Asano,
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationINSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationINTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS
INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS Table of Contents Overview SeQuent Please - DCB Scientific Publications SeQuent Please
More informationA Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience
A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research The Cardiovascular
More informationDRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS
DRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS *Alessandro Durante, 1 Pietro Leonida Laforgia 2 1. Ospedale Valduce, Como, Italy 2. Università degli Studi di Milano, Milan, Italy *Correspondence
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST In the last five years, I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik,
More informationas a Mechanism of Stent Failure
In-Stent t Neoatherosclerosis e osc e os s as a Mechanism of Stent Failure Soo-Jin Kang MD., PhD. University of Ulsan College of Medicine, Heart Institute Asan Medical Center, Seoul, Korea Disclosure I
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationNext Generation Drug- eluting Stent : Will It Solve the Problem?
Next Generation Drug- eluting Stent : Will It Solve the Problem? Yangsoo Jang, M.D., Ph.D, FACC Severance Cardiovascular Hospital Yonsei University Healthcare System Commercially Available DES An Epidemic
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationCalcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease
Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease Thomas M. Shimshak, MD Heart and Vascular Center Florida Hospital Heartland Medical Center
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationDrug delivery to the vessel wall: Coated balloons and the role of the excipient
Drug delivery to the vessel wall: Coated balloons and the role of the excipient Nathan Lockwood BioInterface 2015 2015 SurModics, Inc. 1 Evolution of Devices & Therapy: POBA to DCB Balloon angioplasty
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationMULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationDrug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
More informationJournal of the American College of Cardiology Vol. 39, No. 8, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01774-6
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationSuperficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA
: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA Peripheral arterial disease (PAD) of the superficial femoral artery (SFA) is the most common cause of intermittent claudication
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationImportance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study
Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study Gunnar Tepe, MD Romed Klinikum, Rosenheim, Germany On behalf of the DEFINITIVE AR
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationNon stent based intracoronary drug delivery
Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationLeft main coronary artery (LMCA): The proximal segment
Anatomy and Pathology of Left main coronary artery G Nakazawa Tokai Univ. Kanagawa, Japan 1 Anatomy Difinition Left main coronary artery (LMCA): The proximal segment RCA AV LAD LM LCX of the left coronary
More informationProvisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB
Provisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB Dr. Azeem La/b EMO- GVM Centro Cuore Columbus and San Raffaele Scien/fic Ins/tute, Milan, Italy PCI in Coronary Bifurca/ons Up to
More informationBrachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts
Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts Disclosure Speaker name: Matthew T. Menard... x I do not have
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationTurbo-Power. Laser atherectomy catheter. The standard. for ISR
Turbo-Power Laser atherectomy catheter The standard for ISR Vaporize the ISR challenge In-stent restenosis (ISR) Chance of recurring 7 115,000 + /year (U.S.) 1-6 Repeated narrowing of the arteries after
More informationRandomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After Drug-Eluting Stent Implantation
Journal of the American College of Cardiology Vol. 59, No. 12, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.047
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationDrug eluting balloon for bifurcation lesion: is it useful?
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Drug eluting balloon for bifurcation lesion: is it useful? Dr. Bruno Garcia Hospital Universitari Vall Hebrón Barcelona (Spain)
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationEluNIR. Ridaforolimus Eluting Coronary Stent System. Advancing Deliverability for the Road Ahead
Ridaforolimus Eluting Coronary Stent System Advancing Deliverability for the Road Ahead The Coronary Stent System Raising the Bar on Drug-Eluting Stent Technology Introducing the Coronary Stent System,
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationEffectiveness of Paclitaxel-Eluting Balloon Catheter in Patients With Sirolimus-Eluting Stent Restenosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 2, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.10.012 CLINICAL RESEARCH
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More information